Neovasc Inc. (NASDAQ:NVCN – Get Rating) (TSE:NVC) was the recipient of a significant decline in short interest in May. As of May 15th, there was short interest totalling 5,300 shares, a decline of 76.8% from the April 30th total of 22,800 shares. Based on an average daily volume of 13,500 shares, the short-interest ratio is currently 0.4 days.
A number of equities research analysts have issued reports on the stock. HC Wainwright reissued a “buy” rating and set a $125.00 target price on shares of Neovasc in a research note on Friday, March 11th. StockNews.com assumed coverage on shares of Neovasc in a research report on Saturday, May 21st. They issued a “sell” rating on the stock.
Several institutional investors and hedge funds have recently made changes to their positions in the company. Citadel Advisors LLC bought a new position in Neovasc during the fourth quarter valued at about $74,000. Renaissance Technologies LLC acquired a new stake in Neovasc in the 4th quarter valued at $67,000. Goldman Sachs Group Inc. acquired a new position in Neovasc during the second quarter worth $70,000. Susquehanna International Group LLP bought a new position in shares of Neovasc during the fourth quarter valued at $26,000. Finally, UBS Group AG boosted its position in Neovasc by 564.9% in the third quarter. UBS Group AG now owns 34,701 shares of the medical equipment provider’s stock valued at $25,000 after buying an additional 29,482 shares in the last quarter. 2.42% of the stock is owned by institutional investors and hedge funds.
Neovasc (NASDAQ:NVCN – Get Rating) (TSE:NVC) last announced its quarterly earnings data on Thursday, March 10th. The medical equipment provider reported ($2.25) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.50) by $0.25. The business had revenue of $0.76 million for the quarter, compared to the consensus estimate of $0.80 million. Neovasc had a negative net margin of 1,192.20% and a negative return on equity of 50.69%. As a group, analysts anticipate that Neovasc will post -5 earnings per share for the current year.
Neovasc Company Profile (Get Rating)
Neovasc Inc, a specialty medical device company, develops, manufactures, and markets products for cardiovascular marketplace in Europe and internationally. Its products include the Tiara technology for the transcatheter treatment of mitral valve disease; and the Neovasc Reducer for the treatment of refractory angina.
- Get a free copy of the StockNews.com research report on Neovasc (NVCN)
- Dentsply Stock is Repricing Itself
- Is Zoom Video (NASDAQ: ZM) Starting To Bottom Out?
- Short-Covering Begins In Big Lots
- Agilent Technologies Is Bottoming But Don’t Buy It Yet
- Institutions Ring The Register On Toll Brothers Stock
Want More Great Investing Ideas?
- Bear Market Game Plan!
- The 10 Best Stocks to Own in 2022
- 7 Stocks to Buy and Hold Forever
- 3 Stocks to DOUBLE This Year
Receive News & Ratings for Neovasc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neovasc and related companies with MarketBeat.com's FREE daily email newsletter.